Webinar

The Role and Rationale for Oral Options in the Treatment of Metastatic Breast Cancer

Breast cancer oncologists explore more recent advances using oral chemotherapies to treat metastatic breast cancer.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
Dr Elise Tremblay
Dr Elise Tremblay
4 experts in this video
Related Content
The investigators found that tumor mutational burden and PD-L1 expression, which have traditionally been used as indicators of immunotherapy efficacy, had little predictive value for survival in this cohort. | Image credit: Dragana Gordic - stock.adobe.com
August 14th 2025

Predictive Model Forecasts Advanced NSCLC Outcomes

Jared Kaltwasser
managed care cast logo
August 14th 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM
AJMC
August 14th 2025

Temporal Shift in Prevalence of Heart Failure Diagnoses and Comorbidities Within 2 US Integrated Health Systems

Mario Enrico Canonico, MD, PhD Judith Hsia, MD Shih-Ting Chiu, PhD Pu-Kai Tseng James O. Mudd, MD Joshua D. Remick, MD Bansi Patel, MS Ya-Hsiu Chuang, PhD Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC Marc P. Bonaca, MD, MPH
Managed Care Cast
August 14th 2025

Navigating Risk, Treatment, and Reimbursement in Precision Oncology: Sadie Dobrozsi, MD

Giuliana Grossi Sadie Dobrozsi, MD, MS Interview by Mary Caffrey
Older adult holding several pills and glass of water | Image credit: Kotchakorn – stock.adobe.com
August 14th 2025

Polypharmacy Common in Rheumatoid Arthritis, Driving Risk of Serious Drug Interactions

Hayden E. Klein
The long-term data from DELIVER showed meaningful, sustained improvements in functional outcomes and dystrophin expression, as well as a favorable safety profile in patients with Duchenne muscular dystrophy. | Image credit: OlegKachura - stock.adobe.com
August 14th 2025

DYNE-251 Granted FDA Breakthrough Therapy Designation for DMD

Rose McNulty

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo